| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Xencor Inc (NASDAQ: XNCR)
XNCR Technical Analysis
4
| As on 9th Jun 2023 XNCR STOCK Price closed @ 26.87 and we RECOMMEND Sell for LONG-TERM with Stoploss of 28.97 & Strong Sell for SHORT-TERM with Stoploss of 34.96 we also expect STOCK to react on Following IMPORTANT LEVELS. |
XNCRSTOCK Price
| Open | 27.23 | Change | Price | % |
| High | 27.24 | 1 Day | -0.38 | -1.39 |
| Low | 26.75 | 1 Week | -0.22 | -0.81 |
| Close | 26.87 | 1 Month | -0.03 | -0.11 |
| Volume | 176300 | 1 Year | -12.14 | -31.12 |
| 52 Week High 41.63 | 52 Week Low 19.74 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| XNCR Daily Charts |
XNCR Intraday Charts |
Whats New @ Bazaartrend |
XNCR Free Analysis |
|
|
XNCR Important Levels Intraday
| RESISTANCE | 27.81 |
| RESISTANCE | 27.51 |
| RESISTANCE | 27.32 |
| RESISTANCE | 27.14 |
| SUPPORT | 26.60 |
| SUPPORT | 26.42 |
| SUPPORT | 26.23 |
| SUPPORT | 25.93 |
XNCR Forecast May 2024
| 4th UP Forecast | 45.25 |
| 3rd UP Forecast | 39.36 |
| 2nd UP Forecast | 35.71 |
| 1st UP Forecast | 32.07 |
| 1st DOWN Forecast | 21.67 |
| 2nd DOWN Forecast | 18.03 |
| 3rd DOWN Forecast | 14.38 |
| 4th DOWN Forecast | 8.49 |
XNCR Weekly Forecast
| 4th UP Forecast | 32.52 |
| 3rd UP Forecast | 30.71 |
| 2nd UP Forecast | 29.59 |
| 1st UP Forecast | 28.47 |
| 1st DOWN Forecast | 25.27 |
| 2nd DOWN Forecast | 24.15 |
| 3rd DOWN Forecast | 23.03 |
| 4th DOWN Forecast | 21.22 |
XNCR Forecast2024
| 4th UP Forecast | 71.08 |
| 3rd UP Forecast | 56.9 |
| 2nd UP Forecast | 48.14 |
| 1st UP Forecast | 39.37 |
| 1st DOWN Forecast | 14.37 |
| 2nd DOWN Forecast | 5.6 |
| 3rd DOWN Forecast | -3.16 |
| 4th DOWN Forecast | -17.34 |
Xencor Inc ( NASDAQ USA Symbol : XNCR )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
XNCR Business Profile
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. The company's product candidates include Obexelimab, an immune inhibitor that has completed Phase 2 clinical trial for the treatment of IgG4-related disease and systemic lupus erythematosus, as well as in Phase 1b/2a clinical trial to treat moderate-to-severe rheumatoid arthritis; Plamotamab, a tumor-targeted antibody, which is in Phase 1 clinical trial to treat non-Hodgkin lymphoma; XmAb717, XmAb841, and XmAb104, a bispecific antibody that is in Phase 1 clinical trial to treat patients with selected advanced solid tumors; and Vibecotamab, which is in Phase 1 clinical trial for the treatment of acute myeloid leukemia and other CD123-expressing hematologic malignancies. It is also developing Tidutamab that is in Phase 1 clinical trial to treat neuroendocrine tumors and gastrointestinal stromal tumors; XmAb564 to treat Autoimmune diseases; XmAb819 for the treatment of renal cell carcinoma; and XmAb306/RO7310729, which is in Phase 1 clinical trial to treat solid tumors. In addition, the company provides Monjuvi for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome; and AIMab7195 to reduce blood serum levels of IgE, which mediates allergic responses and allergic disease. It has a collaboration and license agreement with Genentech, MorphoSys AG, Nestlé S.A., Novartis AG, INmune Bio, Inc., Janssen Biotech, Inc., Astellas Pharma, Inc., Amgen Inc., Atreca, Inc., Janssen Biotech, Inc.; and The University of Texas MD Anderson Cancer Center. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California. Address: 111 West Lemon Avenue, Monrovia, CA, United States, 91016
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service